造影剂肾病的相关临床研究进展

Progress of Related Clinical Research on Contrast Induced Nephropathy

随着冠脉介入诊疗术和增强CT在临床中的广泛应用,国内使用造影剂的人群每年达到2~3千万人,造影剂肾病(Contrast Induced Nephropathy, CIN)发生率为1%~5%,每年发生CIN约20~100万例。目前针对CIN并无有效治疗方法,所以临床医生的主要目标是预防,合理使用造影剂及充分水化被认为是最有效的预防手段。本文就CIN诊断标准、危险因素、早期诊断及预防进行综述。

With the extensive clinical application of coronary interventional diagnosis and treatment and enhanced CT, the number of people using contrast media in China reaches 20~30 million each year, and the incidence of Contrast Induced Nephropathy (CIN) is 1%~5%, with about 200,000 to 1 million cases of CIN occurring every year. At present, there is no effective treatment for CIN, so the main goal of clinicians is prevention, and rational use of contrast media and adequate hydration are considered to be the most effective means of prevention. This article reviews the diagnostic criteria, risk factors, early diagnosis and prevention of CIN.